消木丹颗粒治疗非酒精性脂肪性肝病气郁痰阻证临床观察

Clinical Observation of Xiaomudan Granules in the treatment of non-alcoholic fatty liver disease of qi stagnation and obstruction of phlegm syndrome

目的评价消木丹颗粒治疗非酒精性脂肪性肝病(NAFLD)的临床疗效及其安全性。方法将101例NAFLD患者随机分为治疗组(51例)和对照组(50例)。治疗组服用消木丹颗粒,对照组服用多烯磷脂酰胆碱胶囊,2组均治疗12周。观察2组治疗前后临床症状、肝功能、血脂、肝脏超声影像,以及肝/脾CT密度比值的变化。结果治疗12周后,治疗组总有效率为84.3%,对照组为82.0%,2组比较差异无统计学意义(P>0.05)。治疗组在改善患者临床症状、降低血脂等方面优于对照组,差异有统计学意义(P<0.05)。结论消木丹颗粒治疗NAFLD临床疗效较好。

Objective To evaluate the clinical curative effect and safety of Xiaomudan Granules in the treatment of non-alcoholic fatty liver disease（ NAFLD）. Methods 101 NAFLD patients were randomly divided into treatment group（ 51 cases） and control group（ 50cases）. The former group took Xiaomudan Granules and the latter group took Polyene Phosphatidylcholine Capsules both for 12 weeks. Then the changes of clinical symptoms,liver function,blood fat,liver ultrasonic images and the density ratio of the liver to the spleen through CT were observed before and after the treatment in two groups. Results After 12 weeks ＇ treatment, the total effectiveness of treatment group was 84. 3%,that of control group was 82. 0%,and there was no statistical difference between the two groups（ P〉0. 05）. However,the treatment group was better than the control group in clinical symptoms and reducing blood fat,the difference was statistically significant（ P〈0. 05）. Conclusion Xiaomudan Granules has a good curative effect on non-alcoholic fatty liver disease.